Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension. J of Skin. 2022;6(6):s68. doi:10.25251/skin.6.supp.68